Leprosy Mailing List – October 15, 2019
Ref.: (LML) Single-dose rifampicin PEP increased the risk of MB disease
From: Cairns Smith, Aberdeen, UK
Dear Pieter,
I would like to briefly respond to the point raised by Geoff Warne (LML, October 9, 2019). While I understand why he suggests these discussions should be published in a scientific journal, the reality is that no serious scientific journal is likely to publish such material. These analyses would be deemed as 'post hoc analysis', 'subgroup analysis', or more crudely as 'data dredging' by critics creating spurious results.
Cairns Smith
University of Aberdeen, Scotland
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/f9c4fbae-6cb9-4d47-bc1e-e23d918b1bb4%40googlegroups.com.
No comments:
Post a Comment